About BHTS Immunotherapy Research
Cancers Studied in Immunotherapy Research
Immunotherapy is an area of research that studies how the body's immune system may respond to cancer. It is investigational and is not offered as a treatment.
Immunotherapy Research Topics
Researchers study immunotherapy for its potential to target cancer cells. These approaches are investigational and are not offered as a treatment.
Research and Development Process
The research and development process aims to translate scientific research into potential therapies through rigorous testing. It starts with identifying research targets, followed by preclinical testing. Next, clinical trials assess safety and effectiveness. Only if an investigational product succeeds in trials can it gain regulatory approval and be made available to patients, with ongoing monitoring. BH Onco's work is at the research stage.
Discovery and Preclinical Research
Scientists identify the biological mechanisms of cancer and potential targets for therapy. This involves basic research, preclinical testing, and the development of a lead compound, with evaluation of safety before moving forward.
Clinical Trials
The treatment is tested in humans across three phases: Phase I for safety, Phase II for efficacy, and Phase III for comparison with existing treatments. Success in these trials is crucial for moving toward regulatory approval.
Regulatory Approval
Once clinical trials are successful, the treatment undergoes regulatory approval where detailed data on its safety, efficacy, and manufacturing process are submitted to agencies like the FDA. Approval allows the treatment to be prescribed and marketed for patient use.
Post Market Surveillance
Ensures the treatment's long-term safety and effectiveness, while ongoing research may lead to further improvements or new applications. As the treatment is integrated into clinical practice, patients and healthcare providers are educated about its use.
Our Commitment to Research and Education
BHTS Immunotherapy is a research and education organization. We are committed to advancing scientific understanding of cancer immunotherapy. We do not provide medical care or treatment to patients.
our work
Figures Reported in Published Scientific Literature for Four Immunotherapy Approaches: Response Rate, 1-Year Survival, and 6-Month PFS (not BH Onco patient outcomes)
The graph uses three distinct colors to clearly differentiate between the various data sets
Response Rate %
1-Year Overall Survival Rate %
PFS at 6 Months %
